title: Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
abstract: OBJECTIVE
  To establish the pharmacodynamic relationships between drug biodistribution and drug toxicity/efficacy, a comprehensive preclinical evaluation of sphingomyelin/cholesterol (SM/chol) liposomal vincristine and unencapsulated vincristine in mice was undertaken.
  
  
  METHODS
  Pharmaceutically acceptable formulations of unencapsulated vincristine and liposomal vincristine at drug/lipid ratios of 0.05 or 0.10 (wt/wt) were evaluated for toxicity, antitumor activity and pharmacokinetics following intravenous administration.
  
  
  RESULTS
  Mice given liposomal vincristine at 2 mg/kg vincristine had concentrations of vincristine in blood and plasma at least two orders of magnitude greater then those achieved after an identical dose of unencapsulated drug. One day after administration of the liposomal vincristine, there were at least tenfold greater drug quantities, relative to unencapsulated vincristine, in the axillary lymph nodes, heart, inguinal lymph nodes, kidney, liver, skin, small intestines and spleen. Increased plasma and tissue exposure to vincristine as a result of encapsulation in SM/chol liposomes was not associated with increased drug toxicities. Treatment of the murine P388 ascitic tumor with a single intravenous dose of unencapsulated drug at 2, 3 and 4 mg/kg, initiated 1 day after tumor cell inoculation, resulted in a 33 to 38% increase in lifespan. In contrast, long-term survival rates of 50% or more were achieved in all groups treated with the SM/chol liposomal vincristine formulations at doses of 2, 3 and 4 mg/kg. At the 4 mg/kg dose, eight of ten and nine of ten animals survived past day 60 when treated with SM/chol liposomal vincristine prepared at the 0.05 and 0.1 drug/lipid ratios, respectively.
  
  
  CONCLUSIONS
  Overall, increased and prolonged plasma concentrations of vincristine achieved by liposomal encapsulation were correlated with dramatically increased antitumor activity in comparison with the unencapsulated drug, but no correlations could be established between pharmacokinetic parameters and toxicity.
authors.affiliation: Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.
authors.forename: M S
authors.initials: MS
authors.lastname: Webb
authors.forename: P
authors.initials: P
authors.lastname: Logan
authors.forename: P M
authors.initials: PM
authors.lastname: Kanter
authors.forename: G
authors.initials: G
authors.lastname: St-Onge
authors.forename: K
authors.initials: K
authors.lastname: Gelmon
authors.forename: T
authors.initials: T
authors.lastname: Harasym
authors.forename: L D
authors.initials: LD
authors.lastname: Mayer
authors.forename: M B
authors.initials: MB
authors.lastname: Bally
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D002784:Cholesterol; D004337:Drug Carriers; D005260:Female; D008081:Liposomes; D051379:Mice; D013109:Sphingomyelins; D014018:Tissue Distribution; D014750:Vincristine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008081:Liposomes; D013109:Sphingomyelins; D014750:Vincristine; D002784:Cholesterol